Presentation is loading. Please wait.

Presentation is loading. Please wait.

Frequent coamplification of RTKs in MET-amplified EGC

Published byLiisa Leppänen Modified over 5 years ago

Similar presentations

Presentation on theme: "Frequent coamplification of RTKs in MET-amplified EGC"— Presentation transcript:

1 Frequent coamplification of RTKs in MET-amplified EGC
Frequent coamplification of RTKs in MET-amplified EGC. A, CT images of Patient #2 taken before treatment and upon disease progression 1 month after initiation of AMG337. Frequent coamplification of RTKs in MET-amplified EGC. A, CT images of Patient #2 taken before treatment and upon disease progression 1 month after initiation of AMG337. Red arrows, tumor. B, FISH images from Patient #2 showing coamplification of MET and HER2 occurring in the same tumor cells. C, analysis of TCGA data showing cooccurrence of RTK amplification in EGC. D, multicolor FISH analysis of 21 patients with MET-amplified EGC for coamplification of HER2 and/or EGFR in the same tumor cells. E, representative multicolor FISH images from cases in D. Eunice L. Kwak et al. Cancer Discov 2015;5: ©2015 by American Association for Cancer Research

Download ppt "Frequent coamplification of RTKs in MET-amplified EGC"

Similar presentations

Dose-escalation patient response.

Dose-escalation patient response.
Clonal evolution of resistance to sequential ALK inhibitor therapy.

Clonal evolution of resistance to sequential ALK inhibitor therapy.
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
Intrinsic and acquired trastuzumab resistance.

Intrinsic and acquired trastuzumab resistance.
Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.
Figure 2 FXTAS Rating Scale scores for case 1

Figure 2 FXTAS Rating Scale scores for case 1
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,

Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma 

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma 
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
Clinical responses in patients.

Clinical responses in patients.
Representative CT and PET/CT images of three patients with NSCLCs

Representative CT and PET/CT images of three patients with NSCLCs
Clinical courses of patients.

Clinical courses of patients.
Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a patient with idiopathic pulmonary fibrosis (IPF). b) Note.

Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a patient with idiopathic pulmonary fibrosis (IPF). b) Note.
CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer

CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer
Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)
Proposed spiral model for prostate cancer progression.

Proposed spiral model for prostate cancer progression.
Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

Similar presentations

Ads by Google